ACTIVITY OVERVIEW | prIME Oncology presents an educational monograph on the role of neoadjuvant therapy in endocrine-responsive breast cancer. This monograph includes discussions from three different authors covering neoadjuvant endocrine therapy, neoadjuvant chemotherapy, and biologic determinants of systemic therapy. |
AUTHORS | Harry Bear MD, PhD
Virginia Commonwealth University
Richmond, Virginia, United States
Michael Dixon, MD
Edinburgh Breast Unit
Western General Hospital
Edinburgh, United Kingdom
Sandra Swain, MD
Washington Hospital Center
Washington, DC, United States
|
TARGET AUDIENCE | This educational monograph is intended for medical oncologists, radiation oncologists, surgical oncologists, and pathologists actively involved in the management of patients with breast cancer. |
|
|
TABLE OF CONTENTS |
- Neoadjuvant Therapy of Breast Cancer: What We Know and What We Don't
Harry Bear, MD, PhD
- Clinical Debate:
Which Neoadjuvant Treatment Strategy Is Most Appropriate for Endocrine-Responsive Breast Cancer?
- Argument in Favor of Endocrine Therapy
Michael Dixon, MD
- Argument in Favor of Chemotherapy
Sandra Swain, MD
- Biologic Determinants of Systemic Therapy in Early Breast Cancer
Sandra Swain, MD
- Conclusions
Harry Bear, MD,PhD
|
LEARNING OBJECTIVES | Upon completion of this educational activity, participants should be able to:
- Analyze the role of neoadjuvant therapy in endocrine-responsive breast cancer
- Review current neoadjuvant treatment strategies used in endocrine-responsive breast cancer
- Assess the role of gene expression profiles in selecting optimal neoadjuvant therapy for patients
with endocrine-responsive breast cancer
|
|
|
|
This is a prIME Oncology activity.
SUPPORT | This educational monograph is supported by Genomic Health Inc.
|
|
